Quick Takeaways
- Kinnate Biopharma Inc. has 16 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
- Info
- Insider Trading
- Financials
Insider Transactions Reported by 16 Insiders of Kinnate Biopharma Inc.
- Location
- San Diego, CA
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 07 Apr 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Kinnate Biopharma Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| OrbiMed Capital GP VIII LLC | Director, 10%+ Owner | $1,237,500 | Mixed | 17 Feb 2023 | ||
| Richard Thomas Williams | Chief Medical Officer | $175,053 | Mixed | 01 Mar 2024 | ||
| ORBIMED ADVISORS LLC | Director, 10%+ Owner | $0 | Mixed | 03 Apr 2024 | ||
| Carl L. Gordon | Director, 10%+ Owner | $0 | Mixed | 03 Apr 2024 | ||
| James B. Tananbaum | Director, 10%+ Owner | $0 | Mixed | 03 Apr 2024 | ||
| Neha Krishnamohan | Chief Financial Officer | $0 | Mixed | 03 Apr 2024 | ||
| Flaherty Keith T. | Director | $0 | Mixed | 03 Apr 2024 | ||
| Foresite Capital Management IV, LLC | 10%+ Owner | $0 | Mixed | 03 Apr 2024 | ||
| Nima Farzan | CHIEF EXECUTIVE OFFICER, Director | $0 | Mixed | 03 Apr 2024 | ||
| Mark A. Meltz | Coo General Counsel Secretary | $0 | Mixed | 03 Apr 2024 | ||
| Jill DeSimone | Director | Mixed | 03 Apr 2024 | |||
| Michael E. Rome | Director | Mixed | 03 Apr 2024 | |||
| Helen Sabzevari | Director | Mixed | 03 Apr 2024 | |||
| Dean J. Mitchell | Director | Mixed | 03 Apr 2024 | |||
| Laurie Smaldone Alsup | Director | Mixed | 03 Apr 2024 | |||
| Melissa B. Epperly | Director | Mixed | 03 Apr 2024 |
Top shareholders of Kinnate Biopharma Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| OrbiMed Capital GP VIII LLC |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
550,000
|
$1,237,500 | — | 17 Feb 2023 | |
| Richard Thomas Williams |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
class O/S missing
|
67,588
|
$175,053 | — | 01 Mar 2024 |
Recent Insider Transactions by Companies or Individuals for Kinnate Biopharma Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* An asterisk sign (*) next to the price indicates that the price is likely invalid.